Sentences with phrase «of the disease of»

Biblical law offers a means for limiting the ravages of the disease of avarice, and as a result it is the Church, not economists, that must lead in offering the corrective.

Many of them have one of the diseases of chronic alcoholism — polyneuropathy, pellagra, cirrhosis of the liver, or others.

They are most likely to talk of a great increase in average life expectancy, of the conquest of the diseases of aging, and of preserving the capacities and vigor of youth.

The use of idols at no time completely ceased, at least in pre-exilic Israel; also, it became obvious that graven images were only the symptom of the disease of idolatry — i.e., the worship of the creature instead of the creator.

The Supreme Court added to public misunderstanding of the disease of alcoholism in its April finding in Traynor v. Turnage and McKelvey v. Turnage.

Both generally focus on eliminating the high - carbohydrate convenience foods that have caused so many of the diseases of affluence in the last century.

The evil irony of the disease of compulsive gambling is that it seeks out those, like Debbie and Glenn, who are brighter than average, tenacious achievers and tough competitors.

An older study in the Archives of Disease of Childhood found that prolonged crying was associated with adverse cognitive development.

Look at the enormous cost of diseases of environmental origin in children — which we've calculated at about $ 55 billion each year for the 4 million babies born in this country.

This weather - based model was then used to predict the impact on severity of the disease of future weather scenarios for the period from 2020 to 2050.

Not exact matches

• Mereo BioPharma, a London - based rare disease drug firm, filed an IPO of up to $ 81 million.

Cornell's mother suffered from heart disease through much of her life, and the two of them lived very modestly off her disability check in working - class White - stone, Queens.

Meanwhile, about half of all Americans have at least one chronic disease, which is accounting for 80 % of the healthcare costs.

Streicher agrees, noting that the IUD's entire anatomy has been revised (they used to look like this), and that modern IUDs do not increase the chance of contracting a pelvic inflammatory disease.

During the session, a trio of experts discussed the opportunities and challenges of a more globalized world, including cross-border clinical trials, the spread of disease and emerging pathogens and managing supply chains.

About 69 million employees in the U.S. say they miss work because of health problems every year, which reduces economic output by $ 260 billion per year, according to the Centers for Disease Control and Prevention.

Made by companies like Gilead, AbbVie, Merck, and others, drugs that treat the disease are listed at tens of thousands of dollars in the U.S..

But as the good doctor tells Fortune's Erika Fry, there is another infectious disease that's even more dangerous to humanity — and that's the «failure of imagination.»

Heart disease is the leading cause of death for men and women in the U.S. Every year over 700,000 Americans have a heart attack and half of those are fatal.

What's more troubling is that the drugs, unlike statins and other common heart disease medications, don't have a whole lot of alternatives.

To try and stop the spread of disease, scientists have started looking into how to quell mosquito populations.

The changing of the food chain around the world has dramatically changed the onset of diseases.»

«We're in a serious jam,» says Gerry Wright, director of the Michael DeGroote Institute for Infectious Disease Research at McMaster University.

«The potion is not a panacea — it does not have a magic power against all diseases,» said a researcher experienced in cockroach - related medicines at the Institute of Materia Medica at the Chinese Academy of Medical Sciences (CAMS) in Beijing.

With a sturdy, adjustable - height tabletop and a range of 0.6 to 6.5 kilometres per hour, I would soon be typing and talking without worrying about the «sitting disease» epidemic that's killing North Americans.

It is not yet known whether his disease is related to his death, although CBC is reporting that he may have died of a heart attack.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Tehrani targeted the most conservative companies in the business, ones that had no presence in a particular class of disease targets, to entice those who might jump on the bandwagon later.

The PGS platform promised genetic risk reports for more than 250 disease at the time — but, after the FDA smackdown, 23andMe was forced to stop marketing the service and pursue a piecemeal strategy of winning regulatory approval of individual tests.

That means that, for the first time ever, Americans won't have to get a prescription to receive plain - English medical reports about their chances of developing diseases like Alzheimer's, Parkinson's disease, celiac disease, and other disorders based on analyses of their genetic makeup.

Not surprisingly, the spread of diseases (not to mention unhealthy lifestyles that lead to diseases) on a global level is much easier than coordinating care, managing supply chains and clinical trials and rolling out treatments.

«It is our hope that by targeting people earlier, we will have a better chance of delaying or preventing the onset of the disease,» said BAI director Dr. Pierre N. Tariot in a statement.

The Bahamian - American physician and special adviser to the Carter Center is one of the key individuals responsible for the eradication of smallpox — a truly terrifying disease that in the 20th century alone killed as many as 300 million people.

Omada's digital therapeutics platform attempts to address disparate health care needs that can be particularly cumbersome for people at risk for chronic diseases like diabetes through a combination of data analytics, user engagement, and the broad goal of preventing these kinds of conditions from developing in the first place.

Highly successful people tend to have the British disease of the stiff upper lip.

The project's launch featured a prominent ALS patient and research advocate: Pat Quinn, co-founder of the ALS Ice Bucket Challenge, an initially - derided social media stunt that went on to raise hundreds of millions of dollars for ALS research and may have spurred important new discoveries about the disease's genetic roots.

He had been following the emerging science of immunotherapy, which is the use and augmentation of the human immune system to fight disease.

One research project, for example, focuses on using robots to recognize the facial reactions of Parkinson's Disease patients who have lost the ability to convey emotion to others because of reduced muscle activity.

I wish I had served as an example of how improving your health now, by losing weight, gaining fitness, and improving your cholesterol might just help you avoid a heart attack or heart disease — and, if you do have a heart problem, might just help mitigate the damage and possibly even save your life.

Darzalex, however, has not yet reached its peak potential as the drug moves into earlier stages of the disease and is being tested on solid tumours like lung cancer.

Eric Dolan, co-founder of software company Neutun Labs, is clear about the importance of the disease that led him to become an entrepreneur.

Sitting for long periods of time puts you at risk of cardiovascular or metabolic diseases.

«If we determine that our [treatment] can prevent or delay the onset of symptoms in healthy yet high - risk populations, this would represent a tremendous breakthrough for those that may face this debilitating disease.»

Psychiatric diseases, since they are the result of a complex mix of genetics, environment, and behavioral factors, require large numbers of people, or what's known as a large sample size.

They're also the sixth leading cause of chronic disease in the US.

A study of increases or decreases in rates of a disease across years, calculated for groups of people, is called an ecologic study.

Biden also used his own family's history to illustrate the importance of detecting disease earlier.

With 90 per cent of Australians at risk of developing a chronic disease and the workplace being where most of us spend up to half our waking hours, it's only right employers become drivers of change.

Founded in 2011, Innovent has built a portfolio of 16 potential products for treating cancer, autoimmune disorders and other diseases, and seven of those are in clinical development.

The acquisition is meant to build on Takeda's forays into drugs for gastrointestinal disorders; TiGenix is on the cusp of securing a European regulatory approval for a treatment for Crohn's disease.